Market Analysis and Insights: Global Polycystic Ovary Syndrome (PCOS) Drugs Market
Due to the COVID-19 pandemic, the global Polycystic Ovary Syndrome (PCOS) Drugs market size is estimated to be worth US$ 3481.5 million in 2022 and is forecast to a readjusted size of US$ 4502.7 million by 2028 with a CAGR of 4.4% during the review period. Fully considering the economic change by this health crisis, Oral Contraceptives accounting for % of the Polycystic Ovary Syndrome (PCOS) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Polycystic Ovary Syndrome (PCOS) Drugs market size is valued at US$ million in 2021, while the US and Europe Polycystic Ovary Syndrome (PCOS) Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Polycystic Ovary Syndrome (PCOS) Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs include Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co. and Ferring Pharmaceuticals, Inc. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Polycystic Ovary Syndrome (PCOS) Drugs Scope and Segment
Polycystic Ovary Syndrome (PCOS) Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Polycystic Ovary Syndrome (PCOS) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral Contraceptives
Antiandrogens
Insulin-Sensitizing Agent
Antidepressant
Anti-Obesity
Segment by Application
Hospital
Clinic
By Company
Sanofi
Novartis AG
Teva Pharmaceutical Industries Limited
Addex Therapeutics Ltd.
BIOCAD
Merck KGaA
AstraZeneca plc.
Bristol Myers Squibb Co.
Ferring Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE